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Abstract
Although a great progress has been made in surgery, radiotherapy and chemotherapy 
for non-small cell lung cancer (NSCLC), the 5-year overall survival rate (OS) remains 
unsatisfactory (approximately 15%). Recently, cytokine-induced killer (CIK) cells treat-
ment as an adoptive immunotherapy has great promises in the scenario of potential new 
approaches for the treatment of lung tumors. Adaptive and innate cellular immunity 
are all important for inhibiting tumor growth and the clearance of cancer. The abilities 
to efficiently kill tumor cells and promote immune responses are the ultimate basic abil-
ity requested to CIK cells treatment. Therefore, we conducted a systematic review to 
evaluate the immunoregulation of CIK cells treatment in NSCLC patients to provide an 
objective reference for clinical decision-making.
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1. Introduction
Lung cancer is a major cause of diagnosed cancer worldwide with a 5-year survival rate of 
less than 15% [1, 2]. Non-small cell lung cancer (NSCLC) accounts for about 80–85% of lung 
malignancies and shows high morbidity, high mortality and low survival rates. Most of these 
NSCLC patients are diagnosed at the late stage leading to a poor prognosis.
So far, the predominant applied cancer treatment methods are still surgery, radiation and 
chemotherapy; however, the effectiveness of these treatments is not completely satisfactory. 
These methods often have limited effects and often fail to completely remove minimal residual 
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cancer cells. Surgery is the predominant treatment method against for NSCLC; however, 
60–70% of patients who receive surgery may eventually develop loco-regional recurrence or 
distant metastasis [3]. Chemotherapy may be useful, but drug resistance and adverse effects 
still remain; therefore, chemotherapy cannot be used for most of the patients due to the poor 
tolerance of the majority of later stage patients. Thus, the more effective and safer treatments 
are urgently needed [4], and tremendous efforts had been done to find new method that can 
offer better prospects to eradicate tumors.
Recently, adoptive immunotherapy is an evolving treatment approach based on the use of 
the immune system to treat cancer. Immunotherapy has become a hot area in cancer research 
and treatment in China. The rapid ex vivo generation of adoptive immune cells is a simpler, 
cheaper, and more efficient way to generate a potent immunotherapeutic product [5, 6]. Since 
the 1980s, there are different forms of adoptive immunotherapy used in clinical trials: lym-
phokine-activated killer cells (LAK), tumor-infiltrating lymphocytes cells (TIL), natural killer 
(NK), γ δ T-cells and cytokine-induced killer (CIK) cells, tumor-associated antigen (TAA)-
specific cytotoxic T-cell (CTL), and other forms of cells have been extensively employed in 
adoptive immunotherapy [7].
Among them, CIK cells are a heterogeneous population of ex-vivo expanded T lymphocytes 
with diverse T-cell receptor (TCR) specificities and are endowed with nonmajor histocom-
patibility complex (MHC)-restricted activities against tumor cells. The antitumor activity is 
mainly, even if not exclusively, associated with the CD3+CD56+ cells [8]. The antitumor effects 
of CIK cells have been described against a number of hematologic and solid malignancies 
both in vitro and vivo. In vitro, CIK cells can kill tumor cells directly [9–11] and improve 
apoptosis of tumor cells [12], CIK cells also can reverse the drug resistance of A549/DDP [13], 
and other study found that CIK can alter the cytokine secretion profiles of some immune cells 
[14]. In vivo, CIK cells also showed significant antitumor activity in animal studies and clinical 
trials. In the severe combined immunodeficiency (SCID) mouse model, human CIK cells infu-
sion significantly prolongs the survival of SCID mice when compared with control animals or 
animals infused with LAK cells [15]. In other studies, using the SCID model, CIK cells have 
in vivo antitumor activity against a number of hematopoietic and solid tumors [16]. Since 
1991, CIK cells were reported by Schmidt-Wolf [15], and several clinical trials have been stud-
ied. The application of CIK cells as an adoptive immunotherapy is important for the treatment 
of cancer, since several clinical studies have confirmed the safety of CIK therapy for patients 
[17, 18]. Numerous clinical studies have been recently performed, whereby adjuvant infusions 
of CIK cells following surgical resection or chemotherapy demonstrated a significant increase 
in survival time [19, 20]. The first clinical study included 10 patients with metastatic renal car-
cinoma, colorectal cancer and lymphoma. One patient with lymphoma obtained a complete 
response while six patients had progressive diseases and three patients did not experience 
any change [21, 22]. Other clinical trials subsequently confirmed the safety and benefit of CIK 
cell-based therapy along with demonstration of initial clinical activity [23, 24]. But, in a recent 
review, it is reported that patients with localized NSCLC (stages I–III) using immunotherapy 
(excluding checkpoint inhibitors) did not get a survival benefit [25].
The host immune system plays a critical role in tumor surveillance and rejection. Innate and 
adaptive cellular immunity are all important for against tumor growth and the clearance of 
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cancer. Lung cancer is not typically regarded as an “immunogenic” malignancy, a growing 
body of evidence suggests that immune responses to lung tumors might be present, and 
their magnitude might correlate with patient outcome. According to previous studies, cancer 
patients have some dysfunctions in cellular immunity, including innate and adaptive immune 
responses [26]. Because of the low immune functions of lung cancer patients, effective immune 
response cannot be achieved. That is one of the reasons that malignant tumors are incurable 
[27, 28]. Autoimmune disorders in peripheral blood of lung cancer patients are demonstrated 
by lower levels of CD4+T, NK cells, DCs and higher levels of CD8+T cells [29–31]. Several stud-
ies showed that in peripheral blood, increased number of inhibitory cells such as regulatory 
T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) and inhibitory molecular such 
as PD-1 TIM-3 expressed on lymphocytes has been observed in patients with NSCLC, and other 
cancers [32–34]. Otherwise, in tumors tissue there are local immunological changes. Tumor-
infiltrating lymphocytes (TILs) may play an important role in cell-mediated immunological 
destruction of tumors. Many studies demonstrated that there are more T-cells in tumors tissue 
in NSCLC compared with that in normal tissue [35, 36]. Accumulating evidence shows that 
levels of TILs are associated with improved recurrence-free survival in NSCLC patients as well 
as a reduced likelihood of systemic recurrence [37, 38]. A high density of tumor-infiltrating 
Tregs was reported to be associated with the recurrence of resected NSCLC [39].
The abilities to efficiently kill tumor cells and promote immune responses are the ultimate 
basic ability requested to adoptive immunotherapy. The number of immune cells particu-
larly Th1 cells, CD8+ T-cells, and NK, NK T-cells is associated with the survival of cancer 
patients. Such antitumor cellular immune responses can be greatly enhanced by adoptive 
transfer of CIK cells [40, 41]. However, the immune regulation role of CIK cells treatment 
remains controversial. Therefore, in the present study, we conducted a review to evaluate the 
immunoregulation of CIK cells treatment in NSCLC patients, in order to provide an objective 
reference for clinical decision-making.
2. Immunoregulation of CIK cells treatment in NSCLC patients
2.1. The changes of lymphocytes of NSCLC patients in peripheral blood
According to previous studies, cancer patients exhibit certain dysfunctions in cellular immu-
nity, including innate and adaptive immune responses [26]. Due to the low immune function 
displayed by patients with lung cancer, effective immune response cannot be achieved, and 
this is one of the reasons why malignant tumors are incurable [27, 28]. Autoimmune disorders 
in patients with lung cancer are demonstrated by reduced levels of CD4+ and CD3+CD56+ 
cells, and increased levels of CD8+ cells [29, 30]. The response of the human immune system 
against tumors mainly depends on cellular immunity [42]. CD3+ T-cells are mature T-cells, 
while CD4+ T-cells are considered to have a predefined role as Th cells [43]. It has been dem-
onstrated that cytotoxicity against tumors is dependent on an appropriate interaction between 
CD4+ and CD8+ T-cells [44]. However, the ratios of T lymphocyte subsets in peripheral blood 
are usually disordered in cancer patients [45, 46]. The proportion of these cells in the human 
body must remain constant in order to maintain its optimal state of balance and participate 
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in cellular immune surveillance [47]. NK and NK T-cells are effector cells, which are involved 
in the immune response against tumors during the early stages of tumor development [48]. 
These cells do not require any specific antibodies or presensitized lymphocytes to exert their 
function and may be rapidly activated to suppress and destroy a variety of tumor cells [49]. 
In addition, NK and NK T-cells are more lethal upon being activated by lymphokines [49].
Many studies including our study found that the average percentage of CD3+CD4+, CD3+ and 
NK T-cells, as well as the levels of IFN-γ following several treatment courses, were signifi-
cantly higher than the values observed prior to CIK cells treatment [50–52]. Of course, there 
are studies found that there are no changes after CIK cells treatment [25]. Here, we have to 
discuss about the course of CIK cells treatment. Fan et al. found that the median OS of the 
CIK cells treatment more than four cycles subgroup was significantly longer than that of less 
than four cycles subgroup [53]. Shi et al. [54] observed that the percentage of CD3+ and CD4+ 
cells, and the ratio of CD4+/CD8+ cells were significantly higher following the first course of 
CIK cells therapy, compared with the values prior to treatment. However, in our study, the 
percentages of CD3+ and CD3+CD4+ cells were observed to be no change following only one 
course of CIK cells therapy, which may be due to the difference in the detection time point 
(1 month in our study vs. 2 weeks in the study by Shi et al. subsequent to each course), and 
this result was consistent with others. Jin et al. [55] reported that only one treatment course 
of CIK cells treatment was unable to improve the immune function in patients with lung can-
cer. Several researches have reported that CD3+, CD3+CD4+ and other immune cells peaked 
at 4 weeks following CIK cells treatment, while circulating CIK cells persisted for ≤2 weeks 
following infusion [22]. Those studies suggested that several courses of CIK cells treatment 
would be required to achieve a stable effect [22, 55]. Therefore, to gain therapeutic efficacy, 
multiple courses of therapy should be administered to the patients.
Otherwise, the treatment done before CIK cells treatment may affect the immune status of 
NSCLS patients [50]. Thus, the treatments administered to the patients prior to CIK cells 
therapy seemed to affect the outcome, since more courses were required to achieve effective 
antitumor immune responses. At present, there is controversy regarding the number of cells 
required to be infused in CIK cells therapy, since the antitumor activity of CIK cells is mainly 
associated with the CD3+CD56+ fraction, rather than the CD8+ fraction, which constitutes the 
highest percentage of CIK cells [56]. A previous study suggested that the improvements in 
immune function exerted by CIK cells were affected by the number of CIK cells [22]. In our 
study, we found that the number of CD3+CD4+ and CD3+ T lymphocytes did not change fol-
lowing each course of CIK cells treatment. These demonstrated that the number of CIK cells 
did not affect lymphocyte-associated functions. By contrast, the number of NK and NK T-cells 
increased with the increase in the percentage of CD3+CD56+ cells, which enabled the patients 
to effectively kill tumor cells.
In most studies, patients received autologous CIK cells, allogeneic CIK cells may be appli-
cable in the combination treatment in NSCLC [57, 58], median progression-free survival 
(mPFS) of allogeneic CIK cells treatment group was significantly longer that of control 
group [57]. The study found that the levels of IL-2 and IFN-γ in serum did not differ signifi-
cantly between the two groups both before and after the treatment. Moreover, there were 
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no obvious changes in the percentage of CD3+, CD3+CD4+, CD3+CD8+, CD4+/CD8+ T-cell ratio 
and NK cells before and after treatment. Wang et al. found that after allogeneic CIK cells 
treatment, the outcomes of immune function remained unchanged, but the median OS was 
higher in NSCLC patients receiving allogeneic CIK cells than control group [58]. The CIK 
cells used in clinical treatment are mostly induced by PBMC in the peripheral blood of 
patients with tumors. Autologous CIK cells may have the ability to recognize the surface 
markers of tumor cells and have strong anti-tumor activity. However, in recent years, it 
has been suggested that low immunity and poor activity of immune cell in patients with 
tumors may affect the efficacy of CIK cell therapy. Comparative studies of autologous and 
allogeneic CIK cells treatment have not been reported in lung cancer clinical study. One 
study had found that semi-allogeneic DC-CIK cells had a stronger anti-tumor effect than 
did autologous CIK cells in vitro [59]. The reason for this is that the immune function of can-
cer patients is broken. The CIK cells induced by PBMC in tumor patients are significantly 
reduced in both quantity and biological activity.
2.2. The changes of Tregs and MDSCs of NSCLC patients in peripheral blood
The response of the human immune system against tumors mainly depends on cellular 
immunity [42]. However, our immune system does not work effectively in the setting of 
malignancy. The reason for this may be the existence of immune suppression [60–62].
Tregs have an important role in suppressing adaptive immune responses and maintaining 
immune tolerance [63]. At the same time, the existence of Tregs may downregulate tumor-
specific immunity. Tregs interact with various immune cell types, CD8+ T-cells [64], natural 
killer (NK) cells [65], and natural killer T (NKT) cells [66], thus, Tregs may have an important 
impact on cancer immune escape. Several studies have reported that the number of Tregs 
has increased in patients with NSCLC and other cancers [33, 67, 68]. It was reported that the 
percentage of Tregs was significantly reduced at week 2 after CIK cells treatment compared 
with the baseline and remained low at week 4 [51]. The decreasing of Treg was related with 
treatment cycle. Baodan Yu et al. found that significant reduction of Tregs frequency were 
presented in patients received with more than three cycles of CIK cells treatment compared 
with patients with less than three cycles of treatment [69]. In addition, inhibitory cytokines 
TGF-β as well as IL-10 were also decreased [51, 69].
MDSCs are heterogeneous population of myeloid cells known to exhibit potent suppres-
sion of T-cell proliferation and cytokine production [70–72]. Several evidence showed that 
MDSCs have a role in lung tumor growth and progression [73, 74]. In NSCLC patients 
MDSCs were reported in the peripheral blood [75, 76] and MDSCs were significantly 
higher compared with the healthy volunteers and were associated with poorer PFS [77]. 
In case of SCLC, preliminary results from a randomized phase II trial have shown that 
all-trans-retinoic acid (ATRA)-induced depletion of MDSCs may increase the immune 
response to DC-based vaccination to 42% [78]. Two Chinese articles found that CIK cells 
treatment can decrease the level of MDSCs in peripheral blood in malignant melanoma 
and gastrointestinal carcinomas patients. But, we did not find any literature to study the 
role of CIK cells on MDSCs in NSCLC patients.
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2.3. The changes of immune cells of NSCLC patients in tumor tissue
A malignant tumor is not merely an accumulation of neoplastic cells, but also constitutes a 
microenvironment including endothelial cells, fibroblasts, structural components, and infil-
trating immune cells that impact tumor development, invasion, metastasis, and outcome [79]. 
More recently, Fridman et al. reviewed that TILs was associated with clinical outcome in 
several cancers, including lung cancer [80]. All immune cell types might be found in a tumor 
such as CD4+ T-cells, CD8+ T-cells, macrophages, dendritic cells (DCs), mast cells, NK cells, 
memory cells, Tregs cells.
CD4+ T and CD8+ cells are the two major subsets of T lymphocytes and have different roles on 
tumor immunity within the tumor tissue [81]. Wakabayashi et al. [82] found that CD4+ T-cells 
but not CD8+ T-cells in cancer cell nests are associated with a better prognosis in NSCLC 
patients. Another study found that infiltrating CD8+ T-cells and CD4+ T-cells in NSCLC may 
work together to suppress cancer progression [83]. MDSCs were found in lymph nodes and 
tumor tissue of patients with NSCLC [84]. In mouse model, researchers found that CIK cells 
can inhibit the accumulation of MDSCs in the tumor [85]. But, we did not find any literature 
to study the role of CIK cells on infiltrating T-cells and MDSCs in patients with NSCLC. This 
may have been the result of the difficult access to tumor tissue, and relatively little research 
was done in vivo about the CIK cells, especially the studies published in high-level journals. 
Our research team may add these studies to their work in the future.
2.4. Immune checkpoint in NSCLC patients
In the setting of malignancy, immune suppression exists. Except the abovementioned aspects, 
immune checkpoint is another essential mechanism of immune suppression. These immune 
checkpoint included cytotoxic T lymphocyte antigen 4 (CTLA4), programmed death protein 
1 (PD-1), lymphocyte activation gene 3 protein (LAG3), T-cell immunoglobulin domain and 
mucin domain 3 (TIM3), T-cell immunoreceptor with Ig and ITIM domains (TIGIT), and B and 
T lymphocyte attenuator (BTLA) [86]. They can inhibit the development and proliferation of 
lymphocytes [87]. These checkpoint expressed on T-cells was found in peripheral blood and 
tumor tissue have limited ability to effectively eliminate tumors, have gained considerable 
attention and PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in 
non-small cell lung cancer [88, 89]. These molecules were found expressed on CIK cells [60]. The 
majority of these molecules, except BTLA were increased during CIK cells culture. But articles 
about the effect of CIK cells treatment on these molecules was very little in NSCLC patients, we 
only found one Chinese article found that after CIK cells treatment, the expression of PD-1 in 
peripheral blood decreased, and the decreasing was associated with the clinical stage of NSCLC.
2.5. Cytokines in NSCLC patients
In the process of ex-vivo expansion, cytokines play a decisive role in the differentiation and 
function of CIK. Only the addition of cytokines in vitro can induce peripheral blood mono-
cytes (PBMCs) to differentiate into CIK cells. Importantly, different cultures affected the toxic-
ity of CIK cells [15]. In the process of killing tumors in vivo, CIK can secrete a large number of 
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IL-2, IFN-γ, TNF-α, and GM-CSF and other cytokines. It can not only play an anti-tumor role 
directly, but also regulate the immune system of the body, and to stimulate cell proliferation 
and differentiation, and further enhance the cytotoxic activity of immune cells. Immune bal-
ance is controlled by the balance of cytokines produced by two distinct helper T-cell subsets, 
Th1 and Th2 cells [90, 91]. Our study found that the levels of IFN-γ following several treatment 
courses were significantly higher than the values observed prior to CIK cells treatment. The 
levels of IL-2, in vitro and in vivo, were elevated in CIK cells treatment group [12]. The serum 
levels of IL-4 and IL-6 in tumor-bearing patients were elevated after immunotherapy, and 
IFN-γ and IL-6 levels in patients with resected NSCLC were significantly increased. Otherwise, 
Li et al. have also shown that CIK cells treatment increased Th1 cytokines in patients who have 
no progression, but in patients who had developed metastasis had no change [92]. Successful 
immunotherapeutic interventions should overcome Th2 immunity by promoting and restor-
ing antitumor Th1 immune response to achieve better clinical benefits [93].
3. Conclusion
In recent years, with the gradual clearer of tumor immunity regulation mechanism and the 
continuous improvement of gene transformation technology, tumor immunotherapy has been 
developed unprecedentedly. From the nonspecific immune stimulating agent to tumor vac-
cine, then monoclonal antibody and adoptive cellular immunotherapy for immune checkpoint 
blockade, therapeutic immune technology innovation provides more weapons for the human 
resistance tumor. Especially in the recent 5 years, with the rise of immunotherapy for immu-
nological checkpoints and CAR-T-cell, immunotherapy has become more and more popular. 
Nonspecific immunotherapy, such as CIK, DC-CIK or NK cells, is widely used in China at 
present. These kinds of innate immune cells as the first immune defense cells, although the 
specific killing effect may be less than CAR-T, TCR-T, but these nonspecific cells play a positive 
role in lowering recurrence rate, improving tolerance of chemotherapy, improving life quality 
and prolonging the period of survival. However, the curative effect of recurrent and refractory 
tumors is limited to a small number of typical cases, and there is no evidence-based supports 
for prospective, randomized controlled trials. Besides, the combination of PD-1 antibody and 
CTLA-4 antibody is also easy to cause autoimmunity. The instability of tumor cells is also easy 
to form tumor heterogeneity. There is some progress in the research of CAR-T in the hema-
tologic malignancies, but there are many problems in the treatment of solid tumors for CAR-
T. Generally speaking, tumor immunotherapy is progressing faster and has many advantages. 
But if we want to apply for large-scale clinical application, we need to do a lot of research work.
Several articles had reported the safety and efficacy of CIK-cell therapy. Current studies 
on the immunomodulatory effects of CIK-cell therapy have focused on T lymphocytes and 
Treg in peripheral blood. It is much more challenging to study the relationship between 
CIK cells and immune system. Immune system is dynastic and complex, and a lot of other 
aspects are in the volume of the complex. The role of CIK cells on immune responses was 
associated with host factors. Not only cellular immunity we mentioned above but also 
humoral immunity get involved in tumor immunity. Tumor is characterized by distinct 
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individual differences, the same disease, different stages, and different pathological types, 
resulting in different outcomes. Immune system had important roles in these processes. 
Thus, we evaluate the immune function of the patient and analyze the status of each patient 
itself, which are significantly related to the final outcome. The ultimate goal of precision 
immunology for cancer is to select the patients who are most likely to benefit from a par-
ticular immunotherapy.
With the development of new technologies to dynamically detect the cancer-immune system 
interaction and at the same time taking into account the particularity of different groups of 
people, precision cancer immunology and the evaluation of immune function will be applied 
more widely, improving diagnosis and treatment of NSCLC patients.
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